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Background: The primary aim of the study was to investigate the cytokine/
chemokine response in the kidney, lung, and liver following acute kidney injury
(AKI). The secondary aim was to test whether α-melanocyte-stimulating hormone
(α-MSH) could prevent a reduction in organ function, and attenuate the inﬂamma-
tory cytokine/chemokine response within the kidney, lung, and liver following AKI
in rats with or without preexisting chronic kidney disease (CKD).
Methods: A two-stage animal model, in which AKI was induced in rats with
preexisting CKD, induced by 5/6 nephrectomy (Nx), was used. Six weeks later, AKI
was induced by intestinal ischemia and reperfusion (IIR). Sham procedures [S(Nx)
and S(IIR)] were also performed.
Results: Increasing levels of serum creatinine (sCr) demonstrated progressive
development of CKD in response to Nx, and following IIR sCr levels increased
further signiﬁcantly, except in the S(Nx) group treated with α-MSH. However, no
signiﬁcant differences in the fractional increase in sCr were observed between any
of the groups exposed to IIR. In kidney, lung, and liver tissue the levels of interleukin
(IL)-1β were signiﬁcantly higher in rats undergoing IIR when compared to the S(IIR)
and control rats. The same pattern was observed for the chemokine monocyte
chemoattractant protein (MCP)-1 in lung and liver tissue. Furthermore, kidney IL-1β
and RANTES levels were signiﬁcantly increased after IIR in the Nx rats compared to
the S(Nx) rats.
Conclusion: Both the functional parameters and the cytokine/chemokine response
are as dramatic when AKI is superimposed onto CKD as onto non-CKD. No
convincing protective effect of α-MSH was detected.
& 2014. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).n Society of Nephrology. Published by Elsevier. This is an open access article under the CC BY-NC-ND
c-nd/4.0/).
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It is well accepted that preexisting chronic kidney disease
(CKD) increases a patient’s risk of developing acute kidney injury
(AKI), moreover the risk increases in proportion to the respective
CKD stage [1,2]. Furthermore, any episode of AKI in a patient
with underlying CKD substantially increases the rate of transi-
tion to end-stage renal disease (ESRD), mostly because of the
additional damage in the already compromised kidneys [3,4].
This association between CKD and AKI, has been widely
supported epidemiologically, but only to a lesser extent biologi-
cally [5–9]. Therefore, we recently developed a two-stage animal
model in which CKD was introduced prior to AKI. Brieﬂy, CKD
was induced by 5/6 nephrectomy (Nx) and AKI by intestinal
ischemia and reperfusion (IIR). The latter leads to systemic
inﬂammation and ultimately multiple organ failure (MOF) [10]
and AKI [11,12]. This systemic inﬂammation initiates a release of
different proinﬂammatory mediators (e.g., cytokines, chemo-
kines, and leukocytes) into the systemic circulation [13].
Together these mediators induce generalized microvascular
injury, which culminate in MOF, including acute pulmonary,
hepatic, and renal injury [11,12,14,15]. This form of “hypoxic
AKI” is fundamentally different from the often-studied warm
ischemia and reperfusion (IR) AKI model. In this model, a
complete interruption of renal blood ﬂow, for various periods
of time, by renal artery occlusion is used to induce AKI. Although
this clamp approach is often used, it is clearly different from
human AKI, in which most cases occur after systemic hemody-
namic derangement rather than isolated renal artery IR [16–19].
We hypothesize that CKD in rodents exacerbates the
inﬂammatory response within the kidney as well as remote
organs after IIR. Moreover, we hypothesize that a single dose
of the anti-inﬂammatory drug, α-melanocyte-stimulating hor-
mone (α-MSH), administered intravenously, attenuates the
inﬂammatory response after IIR.
α-MSH is a neuropeptide with broad anti-inﬂammatory
properties. It has been shown to inhibit tissue injury in
different experimental models of inﬂammatory organ failure.
Speciﬁcally, it has been shown to protect against intestinalFigure 1. Experimental design. 5/6 Nephrectomy (Nx) was performed in
weeks after Nx, intestinal ischemia and reperfusion (IIR) were performed. Sh
control group was not subjected to any surgical procedures. The arrows indic
reperfusion; MSH, melanocyte-stimulating hormone; Nx, nephrectomy; S(Nand renal IR injury [20,21] and liver injury during endotoxemia
[22]. Themechanisms of action arewide-ranging: (1) inhibiting
production and actions of proinﬂammatory cytokines and
chemokines [22,23]; (2) inhibiting neutrophil migration and
inﬁltration into the tissue [22,23]; and (3) increasing the
production of the anti-inﬂammatory cytokine interleukin
(IL)-10 [24]. Previous studies have reported the beneﬁcial
effects of α-MSH in a dose of 200 μg/g in rodents in various
models of intestinal and renal IR [20,25,26].Methods
Chemicals
α-MSH (500 μg) was purchased from Phoenix Pharmaceu-
ticals (Phoenix Europe GmbH, Karlsruhe, Germany).
Animals
Male Wistar rats were purchased from Taconic (Eiby,
Denmark). Animal experiments were performed in accordance
with the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health and approved
by the Danish Ministry of Justice. All rats were housed in pairs
at room temperature (211C), with alternating 12:12-hour light-
dark cycles, fed with standard rat chow (Altromin, Lage,
Germany), and free access to tap water.
Experimental design and surgery
Rats were randomized according to their initial body weight
into six groups (Fig. 1). Two groups underwent Nx 6 weeks prior
to IIR, whereas two other groups underwent sham Nx [S(Nx)].
Another group underwent only sham IIR [S(IIR)] and a ﬁnal
group of untreated rats served as a control group. At “Before IIR”
(Day 39), which refers to 3 days prior to IIR (Day 42), the rats in
the two Nx groups were re-randomized into two new groups
according to their serum creatinine concentrations (measuredtwo steps, 2/3 left Nx followed by right total (1/1) Nx 1week later. Six
am operations were performed for each surgical procedure as well. The
ate time of blood and urine sampling. d, day; IIR, intestinal ischemia and
x), Sham nephrectomy.
Skott et al / AKI on CKD response 81from the tail vein). This ensured that an equal average
impairment in kidney function within the two Nx groups was
achieved, and the same procedure was performed on the rats in
the two S(Nx) groups. At IIR, a group of Nx rats and S(Nx) rats
received vehicle (0.5 mL 0.9% saline), whereas another group of
Nx rats and S(Nx) rats received α-MSH (200 μg/kg), administered
through the penile vein immediately after intestinal ischemia.
At “Initial” (Day-7), “After 5/6 Nx” (Day 0), “Two weeks after
5/6 Nx” (Day 14), and “Before IIR” (Day 39), blood was obtained
from the tail vein in all vehicle and α-MSH groups. Prior to this,
rats were housed in metabolic cages for 3 days to collect urine.Figure 2. Body weight and organ injury following Nx and IIR. (A) Rats
metabolic cages during the study. By repeated-measures analysis of varian
“Before IIR” post hoc comparisons were performed on pooled data (all Nxþ II
comparisons (Tukey-Kramer) were performed. (B) Renal function was dete
performed on pooled data (all Nxþ IIR groups vs. all S(Nx)þ IIR groups), the
function before and after IIR was determined by measurement of serum ala
All values are presented as mean (7 standard error).
nP o 0.05 vs. S(Nx)þ IIR (pooled data).
† P o 0.05 vs. Nxþ IIR (Vehicle).
‡ P o 0.05 vs. S(Nx)þ IIR (Vehicle).
§ P o 0.05 vs. Nxþ IIR (α-MSH).
|| P o 0.05 vs. S(Nx)þ IIR (α-MSH).
¶ P o 0.05 vs. S(IIR).
** P o 0.05 vs. Control.
d, day; IIR, intestinal ischemia and reperfusion; MSH, melanocyte-stimulatingThe rats in the Control and S(IIR) group had their blood taken at
“Before IIR” (Day 39) and at “Euthanasia” (Day 42). These rats
were not housed in metabolic cages at any time point during
the study.
On the day of surgery animals were anesthetized with 2%
isoﬂurane (Abbot Scandinavia, Solna, Sweden) and 2 L/minute
atmospheric air. Nx was performed by excision of two thirds of
the left kidney, and 1 week later total nephrectomy of the right
kidney. Sham Nx [S(NX)] was performed without any removal
of the renal mass. The amount of kidney tissue removed was
calculated based on the assumption that both kidneys had thewere weighted at each surgical procedure, blood sampling and stay in
ce, all groups had signiﬁcant time  body weight interactions. Until
R groups vs. all S(Nx)þ IIR groups). At “Before IIR” multiple (all 4 groups)
rmined by serum creatinine (sCr). Until “Before IIR” comparisons were
reafter multiple comparisons were performed (Tukey-Kramer). (C) Liver
nine transaminase (sALT).
hormone; Nx, nephrectomy; S(Nx), Sham nephrectomy.
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½ Total nephrectomy weightþPartial nephrectomy weightð Þ
= 2 Total nephrectomy weightð Þ  100: ð1ÞTable 1. Urine and serum analysesn
Group Period SSodium (m
S(Nx) Initial (d –7)
After 5/6 Nx (d 0)
2 w after 5/6 Nx (d 14)
Nx Initial (d –7)
After 5/6 Nx (d 0)
2 w after 5/6 Nx (d 14)
S(Nx)þ IIR (Vehicle) Before IIR (d 39)
S(Nx)þ IIR (α-MSH) Before IIR (d 39)
Nxþ IIR (Vehicle) Before IIR (d 39)
Nxþ IIR (α-MSH) Before IIR (d 39)
n Blood samples were taken at each of the surgical procedures and following
for 24 hours. Values are shown as mean (7 standard error). Until “Before IIR
S(Nx)þ IIR groups)]. At “Before IIR” multiple comparisons (Tukey-Kramer) w
† P o 0.05 vs. S(Nx)þ IIR (pooled data).
‡ P o 0.05 vs. S(Nx)þ IIR (Vehicle).
§ P o 0.05 vs. S(Nx)þ IIR (Vehicle).
d, day; IIR, intestinal ischemia and reperfusion; MSH, melanocyte-stimulati
Figure 3. Blood gases. (A) Arterial blood pH. (B) In the table: pCO2, partial pre
base excess. In the dot plot individual values and mean (horizontal line) are sh
n P o 0.05 vs. Control.
† P o 0.05 vs. S(IIR).
‡ P o 0.05 vs. S(Nx)þ IIR (α-MSH).
IIR, intestinal ischemia and reperfusion; MSH, melanocyte-stimulating hormonIIR was performed 6 weeks after Nx, as previously described
[7]. Brieﬂy, the small intestine was exteriorized through a midline
laparotomy and the superior mesenteric artery (SMA) wasmol/L) SPotassium (mmol/L) UOsm (mosmol/kg H2O)
137.570.5 5.970.1 1,747772
137.370.3 5.370.1 2,023771
138.370.3 5.970.1 1,8637113
137.470.4 6.170.2 1,5747123
137.270.5 5.670.1 632728†
138.570.4 5.870.1 700765†
138.870.4 6.270.3 1,8217137
138.070.5 6.270.3 1,7637160
136.470.5‡ 6.470.2 7637102§
136.570.5‡ 6.470.3 757772§
5/6 nephrectomy. Urine was collected during housing in metabolic cages
” comparisons were performed on pooled data [all Nxþ IIR groups vs. all
ere performed.
ng hormone; Nx, nephrectomy; S(Nx), Sham nephrectomy.
ssure of carbon dioxide; HCO3
–, concentration of bicarbonate; ABE, arterial
own. In the table values are presented as mean (7 standard error).
e; Nx, nephrectomy; S(Nx), Sham nephrectomy.
Figure 4. Lung edema. At the completion of the experiment, the left
lung was excised and immediately weighed. After having been frozen at
–201C for 1 month, the lung was dried at –601C in a vacuum dryer for 48
hours and reweighed. Tissue water content was then calculated.
Individual content and mean (horizontal line) within each group
are shown. IIR, intestinal ischemia and reperfusion; MSH, melanocyte-
stimulating hormone; Nx, nephrectomy; S(Nx), Sham nephrectomy.
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Prior to closing the abdominal wall, 1 mL of saline (371C) was
infused in the peritoneal cavity and 1mL was administered
subcutaneously. The rats were allowed to awaken and were
monitored in cages until 90 minutes after ischemia, following
which euthanasia was performed. Sham IIR [S(IIR)] was performed
by a midline laparotomy and manipulation of the SMA without
occluding it.
During each surgical procedure, rats were placed on a
heated table to maintain rectal temperature at 37.51C. Initially,
at each surgical procedure buprenophium 0.3 mg/kg (Temge-
sic; Reckitt Benckiser, Berkshire, UK) was injected subcuta-
neously to relieve pain, and later administered in the drinking
water at the same dose.
Assessment of renal function
Serum creatinine was determined colorimetrically (Vitros 5.1,
Johnson & Johnson, New Brunswick, NJ, USA). Urine osmolality
was measured using a vapor pressure osmometer (Osmomat 030,
Genotec, Berlin, Germany). Blood was obtained from the tail vein,
apart from at euthanasia, when the blood sample was obtained
from the abdominal aorta. AKI was deﬁned as a statistical
signiﬁcant increase in serum creatinine level.
Measurement of proinﬂammatory cytokines and chemokines
in the lung, kidney, and liver
The proinﬂammatory cytokine IL-1β, anti-inﬂammatory cyto-
kine IL-10, and the chemokines monocyte chemoattractant pro-
tein (MCP)-1 and RANTES were measured in the kidney, lung, and
liver homogenates using Procarta Cytokine Assay kit (Invitrogen A/
S, Taastrup, Denmark) according to the manufacturer's instruc-
tions. The samples were analyzed on a Luminex 100 IS ﬂow
system (Luminex Corporation, Austin, TX, USA). Brieﬂy, the color
code of each bead identiﬁes the target protein being assayed and
the ﬂuorescent intensities on the beads measure target concentra-
tion. The tissue samples were diluted in the assay buffer and
measured in duplicate. Total system raw median ﬂuorescence
intensity (MFI) values were used for calculations of concentrations
(ρg/mL) from four-parameter logistic ﬁtted standard curves using
the StarStation version 2.3 software (Applied Cystometry, Shef-
ﬁeld, UK). The ﬁts expressed by the R-squared value were all 4
0.995. To adjust measurements for differences in total protein
content of the samples, values are expressed in picograms per
gram of protein. Total protein concentration was determined by
the Pierce BCA protein assay kit (BIO-RAD, Hercules, CA, USA).
Lung wet/dry ratio
At the completion of the experiment, the left lung was
excised and immediately weighed. After storage at 201C for a
month it was dried at 601C in a vacuum dryer for 48 hours
and reweighed. Tissue water content was then calculated as:
Wet weight–Dry weightð Þ= Wet weightð Þ  100
and expressed as a percentage: ð2Þ
Arterial blood gas
At euthanasia, arterial blood drawn from the abdominal
aorta was analyzed using an ABL 5 blood gas analyser (Radio-
meter, Copenhagen, Denmark).Liver enzyme
Serum alanine aminotransferase (ALT) was determined
by the Vitros 5.1 system (Ortho Clinical Diagnostics, New
Brunswick, NJ, USA) using slide technology.
Statistical analysis
Data were presented as mean 7 standard error of the mean.
Differences between the groups were examined for statistical
signiﬁcance by analysis of variance. Post hocmultiple comparisons
were performed with the Tukey-Kramer method. Furthermore, a
comparison was performed on pooled data from the Nxþ IIR
groups and S(Nx)þ IIR groups, respectively, until “Before IIR”.
Longitudinal measurements of body weight were analyzed by
repeated-measures analysis of variance to test time dependent
interactions. When the statistical model was signiﬁcant, further
post hoc analyses were performed with the Tukey-Kramer method
for multiple comparisons using STATA version 10.1 (Stata Corpora-
tion, Lakeway Drive College Station, TX, USA). A two-sided P o
0.05 was accepted as statistically signiﬁcant.Results
Physiological data
Body weight increased in all four groups during the 6 weeks
of follow-up after Nx or S(Nx) (Fig. 2A). Already after 5/6
nephrectomy, the body weight of the rats in the Nx groups was
signiﬁcantly lower compared to the rats in the S(Nx) groups.
This difference remained signiﬁcant during the 6 weeks of
follow-up after Nx (Fig. 2A).
During the 6 weeks after Nx, 10% of the Nx rats and 13% of
the S(Nx) rats were excluded. Exclusion criteria were wound
infections, extreme weight loss, and spontaneous death. The
Kidney Res Clin Pract 33 (2014) 79–8884excluded rats were not included in the data analysis at any
time point. On average, 76% (data not shown) of the kidney
mass was removed in the rats that had Nx.Renal function after Nx and S(Nx) respectively
Urine output and water intake were measured in metabolic
cages; “After 5/6 Nx” (Day 0) both urine output and water
intake were signiﬁcantly higher in the Nx rats compared to the
S(Nx) rats (Table 1). Consistent with these changes was a
signiﬁcantly lower urine osmolality in the Nx rats compared to
the S(Nx) rats (Fig. 2B).
After Nx, initial indications of impaired renal function in
the Nx rats were shown by dramatically elevated serum
creatinine (sCr) levels, followed by a drop to a more steady,
but signiﬁcantly higher, level than in the S(Nx) rats
(Fig. 2B).Figure 5. Kidney cytokines. Proinﬂammatory cytokines (IL-1β), anti-inﬂ
measured in whole kidney tissue by multiplex assays. Individual tissue con
n P o 0.05 vs. Nxþ IIR (Vehicle).
† P o 0.05 vs. S(Nx)þ IIR (Vehicle).
‡ P o 0.05 vs. Nxþ IIR (α-MSH).
§ P o 0.05 vs. S(Nx)þ IIR (α-MSH).
|| P o 0.05 vs. S(Nx).
¶ P o 0.05 vs. Control.
IL, interleukin; IIR, intestinal ischemia and reperfusion; MCP, monocyte
nephrectomy; S(Nx), Sham nephrectomy.Elevated organ speciﬁc biomarkers in serum conﬁrmed the
development of MOF, induced by IIR
A signiﬁcant increase [from “Before IIR” (Day 39) to “Eutha-
nasia” (Day 42)] of 54% (76%), 73% (720%), and 73% (721%)
in sCr after IIR was observed in the Nxþ IIR (Vehicle), S(Nx)þ
IIR (Vehicle), and Nxþ IIR (α-MSH) rats, respectively, indicating
that AKI was ongoing until euthanasia (Fig. 2B). No signiﬁcant
increase, 28% (717%) and –9% (710%) in sCr was observed in
the S(Nx)þ IIR (α-MSH) and S(IIR) groups, respectively in the
same period after IIR. There were no signiﬁcant differences in
the fractional increase in sCr between any of the groups
exposed to IIR (P 4 0.05). At “Euthanasia” (Day 42) sCr was
signiﬁcantly higher in the groups exposed to IIR compared
to S(IIR) (Fig. 2B). Moreover sCr was signiﬁcantly higher at
“Euthanasia” (Day 42) in the groups exposed to Nx compared
to S(Nx) in response to IIR (Fig. 2B). There were no signiﬁcant
differences in sCr at “Euthanasia” (Day 42) between the groups
treated with α-MSH compared to vehicle irrespective of Nx orammatory cytokine (IL-10), and chemokines (RANTES, MCP-1) were
centrations and mean (horizontal line) within each group are shown.
chemoattractant protein; MSH, melanocyte-stimulating hormone; Nx,
Skott et al / AKI on CKD response 85S(Nx) prior to IIR. The aforementioned changes in sCr between
“Before IIR” (Day 39) and “Euthanasia” (Day 42) actually took
place because of IIR on the day of IIR surgery, and not during
the 3 days between “Before IIR” (Day 39) and “Euthanasia”
(Day 42). Animal ethics demanded that we did not redraw
blood just prior to the IIR procedure.
There was a tendency for an increase in the liver enzyme ALT
after IIR, although not signiﬁcantly. At “Before IIR” (Day 39) ALT
was signiﬁcantly higher in the Nx and S(Nx) groups, compared to
the S(IIR) and Control groups, respectively (Fig. 2C).Metabolic acidosis was achieved after IIR
After IIR, the pH of the arterial blood was signiﬁcantly
lower in the groups exposed to IIR compared to the S(IIR) and
the Control groups. In the S(IIR) group, pH was signiﬁcantly
lower than in the Control group, reﬂecting that even lapar-
otomy and anesthesia had an effect on blood pH (Fig. 3A).
The groups exposed to IIR had signiﬁcantly lower levels
of HCO3 and arterial base excess (ABE) compared to the S
(IIR) and Control groups, respectively (Fig. 3B). Because pH,
HCO3–, and ABE were signiﬁcantly lower in the groups exposed
to IIR compared to S(IIR), the data indicated that metabolic
acidosis occurred when rats were subjected to IIR.Figure 6. Lung cytokines. Proinﬂammatory cytokines (IL-1β), anti-inﬂamma
in whole lung tissue by multiplex assays. Individual tissue concentrations a
n P o 0.05 vs. S(Nx).
† P o 0.05 vs. Control.
IL, interleukin; IIR, intestinal ischemia and reperfusion; MSH, melanocyte-stAdministration of α-MSH did not signiﬁcantly change any of
the blood gases.Lung edema
As a surrogate for lung edema, lung tissue water content
was calculated. There was no difference in the tissue water
content between any of the groups (Fig. 4).Changes in cytokines and chemokines in kidney, lung, and
liver tissue
In the kidney (Fig. 5), lung (Fig. 6), and liver (Fig. 7) tissue the
levels of IL-1βwere signiﬁcantly higher in the rats undergoing IIR
when compared to S(IIR), except in the S(Nx)þ IIR (α-MSH)
group in the kidney. The same pattern was observed for
chemokine MCP-1 in the lung and liver tissue. Furthermore
IL-1β and RANTES were signiﬁcantly higher in the kidney tissue
in the rats, which prior to IIR were exposed to Nx compared to
sham Nx (Fig. 5).
No differences in the levels of IL-10 within the kidney, liver,
and lung tissue were observed among any of the groups.tory cytokine (IL-10), and chemokines (RANTES, MCP-1) were measured
nd mean (horizontal line) within each group are shown.
imulating hormone; Nx, nephrectomy; S(Nx), Sham nephrectomy.
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In the current study, we evaluated the effects of an
intravenous bolus of α-MSH on IIR-induced AKI, and found
no signiﬁcant protective effect of α-MSH.
Furthermore, we examined the effect of CKD on the severity
of the inﬂammatory cytokine/chemokine response in the
kidney, lung, and liver tissue induced by IIR. The main ﬁnding
was that Nx (CKD) induced an increased cytokine/chemokine
response within the kidney tissue, when compared to S(Nx)
(non-CKD).
Preexisting CKD may predispose to a more severe
inﬂammatory response
In previous work (unpublished data using a similar animal
model and experimental setup) we found that Nx induced an
increased cytokine/chemokine response within the kidney tissue,
when compared to sham Nx. Additionally, the IL-1β response
within the kidney tissue was further increased in the Nx rats
when they were exposed to IIR compared to Nx rats exposed
to sham IIR. In the current study we found that the IL-1β andFigure 7. Liver cytokines. Proinﬂammatory cytokines (IL-1β), anti-inﬂamma
in whole liver tissue by multiplex assays. Individual tissue concentrations a
n P o 0.05 vs. Nxþ IIR (Vehicle).
† P o 0.05 vs. S(Nx)þ IIR (Vehicle).
‡ P o 0.05 vs. S(Nx).
§ P o 0.05 vs. Control.
IL, interleukin; IIR, intestinal ischemia and reperfusion; MSH, melanocyte-stRANTES response within the kidney tissue was signiﬁcantly
higher in the Nx rats when they were exposed to IIR, compared
to the S(Nx) rats exposed to IIR (Fig. 5). Similar ﬁndings have
been observed in plasma IL-6 levels by Leelahavanichkul et al [6]
in an alternative AKI onto CKD model in mice. Others have
reported increased levels of IL-6 and MCP-1 in kidney tissues
after AKI induced by renal IR [13,27–29] in rodents with normal
kidney function prior to AKI.
As mentioned in the Introduction, the renal IR model is
fundamentally different from the AKI model used in the
current study. Thus, we cannot exclude that the intrarenal
inﬂammatory cytokine/chemokine responses found in the
current study could be caused by CKD secondary to Nx, and
not solely by IIR.
Metabolic acidosis after IIR
During IIR profound cardiovascular instability occurs,
marked by hypotension and increasing levels of lactic acid
[7,30]. As a result of the shift to a more anaerobic metabolism
after IIR, metabolic acidosis occurs. In the current study (Fig. 3)
a pH between 7.21 and 7.26 and HCO3– between 17.1 andtory cytokine (IL-10), and chemokines (RANTES, MCP-1) were measured
nd mean (horizontal line) within each group are shown.
imulating hormone; Nx, nephrectomy; S(Nx), Sham nephrectomy.
Skott et al / AKI on CKD response 8722.1 mmol/L was observed in the groups exposed to IIR. This
conﬁrms the ﬁndings of previous studies of IIR in rats with
varying time periods of ischemia and reperfusion, in which a
pH between 7.11 and 7.31 [31,32] and HCO3– between 11.0 and
16.8 mmol/L are presented [31,32]. Additionally, a signiﬁcantly
low level of ABE was found in the groups exposed to IIR
compared to S(IIR). In conclusion, when comparing the IIR
groups with the S(IIR) group, IIR induces metabolic acidosis.
Both anesthesia [33] and laparotomy [31,32] have been
described to profoundly reduce pH. In the current study we
found a lower pH and a higher pCO2 in the S(IIR) group
compared to the Control group (Fig. 3A).
Remote organ injury following IIR
Remote organ failure follows IIR. We observed increasing
levels of serum creatinine (Fig. 3B) and alanine transaminase
(Fig. 3C), reﬂecting acute kidney injury and acute liver injury,
between “Before IIR” and at “Euthanasia”. Unfortunately, we did
not observe any differences in lung tissue water content at
“Euthanasia” as a surrogate for pulmonary edema. Pulmonary
edema is a common ﬁnding in acute lung injury [34], and occurs
because of increased pulmonary microvascular permeability, as
described in the IIR model [14,35]. The lack of differences
between the rats in the current study exposed to IIR, compared
to S(IIR) or the untreated Control, might be explained by the
length of the ischemia period. In previous studies with increasing
levels of pulmonary vascular permeability, intestinal ischemia
periods between 60 minutes and 120 minutes are reported
[14,35]. As mentioned, we used an ischemia period of 45
minutes, because of the increasing mortality reported in studies
with Z 60 minutes [36,37].
α-MSH had no protective effect on AKI induced by IIR
In the current study, we found no signiﬁcant organ protective
effect of an intravenous bolus of α-MSH (200 μg/kg) administered
prior to intestinal reperfusion. This is in contrast to other studies
of primary and secondary AKI in rodents. In renal ischemia and
reperfusion (primary AKI), α-MSH (150–200 μg/kg) has been
shown to decrease renal injury, through neutrophil-indepen-
dent pathways [23,38,39]. In a model of secondary AKI, induced
by lethal cecal ligation and puncture (CLP) in mice, α-MSH
(6.8 μg) prevented a rise in serum creatinine after CLP compared
to vehicle [40].
Furthermore, α-MSH has been shown to protect against
secondary lung injury following renal ischemia and reperfu-
sion [21]. In the cytokine/chemokine measurements in the
lungs, we did not observe any signiﬁcantly acute protective
effect of α-MSH. Additionally, in a murine study, α-MSH (50 μg)
has been shown to prevent lipopolysaccharide (LPS)-induced
hepatic inﬂammation and inhibit production of chemokine
MCP-1 in liver tissue [22]. In the current study we did not
observe differences in liver MCP-1 in the α-MSH treated
groups compared to the vehicle. This may be explained by
the differences in which acute liver injury is induced and the
different methods of measuring MCP-1, Northern blotting
(messenger RNA) versus Multiplex enzyme-linked immuno-
sorbent assay (proteins) in the current study.
The discrepancy in the ﬁndings between the current and
prior studies of the possible organ protective effect of α-MSH
may be explained by the regimen in which α-MSH was
administered: α-MSH was only injected intravenously as abolus of 200 μg/kg through the penile vein immediately after
reperfusion. This was because the aim was to investigate the
acute response of α-MSH treatment in a model of acute MOF in
rodents with or without preexisting CKD.
Limitations of the study
The current study is not without its limitations. First, we
measured cytokines in whole tissue homogenates instead of
plasma, which is used in clinical studies of AKI. The reasons for
this are that a signiﬁcant proportion of the cytokines act via
paracrine mechanisms, and they have a short half-life in
plasma, making them very difﬁcult to detect. Moreover, the
release patterns of each of the individual cytokines are
different, and we only measured cytokines at a single time
point. Late and more “downstream” releases of cytokines are
not detected or evaluated in the current study.
Second, in addition to measuring cytokines/chemokines in
whole tissue homogenates, evaluation of tissue inﬂammation,
for example, by using immunohistochemical detection of
neutrophils and macrophages, could have strengthened the
evaluation of a CKD-exacerbated inﬂammatory response
within the kidney after AKI. Unfortunately, we were not able
to harvest any of the remnant kidney mass for immuno-
histochemistry.Conﬂicts of interest
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